MSI1 and neoplasm: Some studies identify both MSI-1 and MSI-2 as potential therapeutic targets: MSI-1 has been described to enhance BCSC characteristics through proteasome subunit expression regulation [16], and anti-tumor effects subsequent to MSI-2 targeting have been shown in breast cancer [17].